



**HAL**  
open science

## Molecular Determinants of the Cardiometabolic Improvements of Dietary Flavanols Identified by an Integrative Analysis of Nutrigenomic Data From a Systematic Review of Animal Studies

Laurent-Emmanuel Monfoulet, Tatjana Ruskovska, Vladimir Ajdzanovic, Jaroslav Havlik, David Vauzour, Banu Bayram, Irena Krga, Corral Jara Karla Fabiola, Elena Kistanova, Desislava Abadjieva, et al.

### ► To cite this version:

Laurent-Emmanuel Monfoulet, Tatjana Ruskovska, Vladimir Ajdzanovic, Jaroslav Havlik, David Vauzour, et al.. Molecular Determinants of the Cardiometabolic Improvements of Dietary Flavanols Identified by an Integrative Analysis of Nutrigenomic Data From a Systematic Review of Animal Studies. *Molecular Nutrition and Food Research*, 2021, 65 (16), pp.2100227. 10.1002/mnfr.202100227. hal-03246237

**HAL Id: hal-03246237**

**<https://hal.inrae.fr/hal-03246237v1>**

Submitted on 23 Oct 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Molecular determinants of the cardiometabolic improvements of dietary flavanols identified by an integrative analysis of nutrigenomic data from a systematic review of animal studies

Laurent-Emmanuel Monfoulet<sup>1,§</sup>, Tatjana Ruskovska<sup>2</sup>, Vladimir Ajdzanovic<sup>3</sup>, Jaroslav Havlik<sup>4</sup>, David Vauzour<sup>5</sup>, Banu Bayram<sup>6</sup>, Irena Krga<sup>1,7</sup>, Corral Jara Karla Fabiola<sup>1</sup>, Elena Kistanova<sup>8</sup>, Desislava Abadjieva<sup>8</sup>, Marika Massaro<sup>9</sup>, Egeria Scodetti<sup>9</sup>, Eirini Deligiannidou<sup>10</sup>, Christos Kontogiorgis<sup>10</sup>, Anna Arola-Arnal<sup>11</sup>, Evert M. van Schothorst<sup>12</sup>, Christine Morand<sup>1</sup>, Dragan Milenkovic<sup>1,13</sup>

<sup>1</sup> Université Clermont Auvergne, INRAE, UNH, F-63000 Clermont-Ferrand, France

<sup>2</sup> Faculty of Medical Sciences, Goce Delcev University, Stip, North Macedonia

<sup>3</sup> Department of Cytology, Institute for Biological Research “Siniša Stanković” – National Institute of Republic of Serbia, University of Belgrade, 142 Despot Stefan Blvd., Belgrade, Serbia

<sup>4</sup> Department of Food Science, Czech University of Life Sciences Prague, Prague 6 - Suchbát, Czech Republic

<sup>5</sup> Department of Nutrition and Preventive Medicine, Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK

<sup>6</sup> Department of Nutrition and Dietetics, University of Health Sciences, Istanbul, Turkey

<sup>7</sup> Centre of Excellence in Nutrition and Metabolism Research, Institute for Medical Research, National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia

<sup>8</sup> Institute of Biology and Immunology of Reproduction, Bulgarian Academy of Sciences, Sofia, Bulgaria

<sup>9</sup> National Research Council (CNR) Institute of Clinical Physiology, Lecce, Italy

Received: 11/03/2021; Revised: 21/05/2021; Accepted: 27/05/2021

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/mnfr.202100227](#).

This article is protected by copyright. All rights reserved.

<sup>10</sup> Laboratory of Hygiene and Environmental Protection, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece

<sup>11</sup> Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Nutrigenomics Research Group, 43007 Tarragona, Spain

<sup>12</sup> Human and Animal Physiology, Wageningen University, Wageningen, The Netherlands

<sup>13</sup> Department of Internal Medicine, Division of Cardiovascular Medicine, School of Medicine, University of California Davis, Davis, California, 95616, United States of America

<sup>§</sup> Corresponding author:

Laurent-Emmanuel Monfoulet

laurent-emmanuel.monfoulet@inrae.fr

INRAE – Centre Clermont-Auvergne Rhône-Alpes

Unité de Nutrition Humaine, UMR 1019

F-63122 Saint Genès Champanelle, France

## Abstract

Flavanols are important polyphenols of the human diet with extensive demonstrations of their beneficial effects on cardiometabolic health. They contribute to preserve health acting on a large range of cellular processes. The underlying mechanisms of action of flavanols are not fully understood but involve a nutrigenomic regulation. To further capture how the intake of dietary flavanols results in the modulation of gene expression, nutrigenomics data in response to dietary flavanols obtained from animal models of cardiometabolic diseases have been collected and submitted to a bioinformatics analysis. This systematic analysis shows that dietary flavanols modulate a large range of genes mainly involved in endocrine function, fatty acid metabolism, and inflammation. Several regulators of the gene expression have been

predicted and include transcription factors, miRNAs and epigenetic factors. This review highlights the complex and multilevel action of dietary flavanols contributing to their strong potential to preserve cardiometabolic health.

## 1. Introduction

Polyphenols constitute a very large group of plant-derived bioactive compounds that include multiple families structurally distinct, such as stilbenes, phenolic acids, lignans and flavonoids. The flavonoid group can be further divided into six different subclasses based on their chemical structure: flavones, isoflavones, flavanones, flavonols, anthocyanins and flavanols (also known as flavan-3-ols), with these latter being present as both monomeric (catechins) and polymeric (proanthocyanidins) compounds. The group of catechins includes catechin (C), epicatechin (EC), epigallocatechin (EGC), epicatechin gallate (ECG), and epigallocatechin gallate (EGCG). Overall, flavanols represent the most commonly consumed flavonoids and are particularly abundant in (green) tea, cocoa, grapes, apples, red wine, and also in many whole and processed foods and dietary supplements.

A wealth of epidemiological studies has documented an inverse correlation between the intake of polyphenol-rich foods and the incidence of cardiometabolic diseases [1]. More recently, strong meta-analyses of prospective cohort studies have established that high consumption of flavonoids reduced the incidence of cardiovascular diseases (CVD) and type 2 diabetes (T2D), with associations remaining significant when considering individual classes of flavonoids [2, 3]. Regarding flavanols intake and cardiometabolic health, a recent systematic review and meta-analysis of randomized trials and prospective cohort studies concluded on a beneficial effect of flavanols, irrespective of dietary source, on a range of cardiometabolic outcomes [4]. However, this paper also underlined heterogeneity in the meta-analysis leading to a variable strength of evidence for the different outcomes. More

specifically the intake of flavanols can improve cardiometabolic health by increasing the production of vasoprotective agents, especially nitric oxide (NO), by reducing circulating lipids (triglycerides (TG), low-density lipoprotein (LDL)-cholesterol, free fatty acids (FFA)) and their accumulation in liver and adipose tissues, by preventing weight gain, improving glucose homeostasis (i.e., blood glucose and insulin levels) and lowering blood pressure [5-8]. These cardioprotective effects have been demonstrated to be linked to the activation of several pro-survival cellular pathways that involve metabolic intermediates, microRNAs (miRNAs), sirtuins and mediators of the reperfusion injury salvage kinases (RISK), and survivor activating factor enhancement (SAFE) pathways [9]. Based on single dosing of flavanols administered in animal models, it was shown that the enhancement of energy expenditure induced by flavanols might represent a plausible explanation for their anti-obesity effects [10], which appeared to be associated with increased catecholamine secretion [11]. Of note, the flavanol-induced effects are dependent on the dose and the background diet [12]. Grapes and grape juice (rich in catechin and epicatechin) seem capable of ameliorating endothelial function and reducing LDL oxidation via an antioxidant activity [13, 14]. Flavanols were also shown to have mitochondrial biogenesis-inducing effects in skeletal muscle [15], which might underlie part of their positive effects on glucose homeostasis observed in both animal models and humans [16-18].

Cumulatively, it appears that a plethora of different mechanisms have been identified underlying the flavanol-induced effects *in vivo*, urging us to review here those solely for the flavanols-induced effects in relation to cardiometabolic risk improvement. The use of preclinical animal studies is appropriate to investigate, under highly controlled conditions, the physiological effects following specific dietary intakes. These studies are of particular relevance as they allow to establish a causality relationship between flavanols consumption and cardiometabolic outcomes and subsequently contribute to help elucidate tissue-specific

cellular mechanisms. In particular, animal intervention studies offer a unique opportunity to address the systemic interaction of the underlying transcriptional and cellular regulatory networks. On this background, we decided to perform a systematic and integrative analysis of the nutrigenomic effects exerted by flavanols in different animal models of cardiometabolic disease (i.e., the effect of flavanols on gene expression) with the aim to identify the key molecular determinants involved in the cardiometabolic protective effects of these dietary components.

## 2. Methods

The present study complied with the Preferred Reporting Items for Systematic Reviews statement [19].

### 2.1 Literature search strategy

A comprehensive search on PubMed and Web of Science was conducted in December 2019. The search included keywords referring to bioactives (catechin, epicatechin, epigallocatechin gallate, and proanthocyanidin), type of study and animal species (*in vivo*, animal experimentation, animal model, mouse, mice, murine, musculus, rats, Rattus, rodent, rabbit, Cuniculus, dog, Canis, Guinea Pig, cat, swine, pigs, porcus), nutrigenomic analysis (gene expression, miRNA, transcripts, nutrigenomic, TaqMan low density array (TLDA), microarray, genomic, mRNA, western-blot), target tissues and cardiometabolic outcomes (aorta, vessel, vascular, heart, fat, adipose tissue, liver, muscle, circulating cells, blood cells, peripheral blood mononuclear cells (PBMC), blood pressure, hypertension, myogenic tone, vascular tone, atherosclerosis, LDL-cholesterol, high-density lipoprotein (HDL)-cholesterol, cholesterol, TG, body weight, inflammatory markers, insulin, Hometostatic Model Assessment of Insulin Resistance (HOMA-IR), glucose, glycemia, adipokines, anti-oxidant, homocysteinemia).

## 2.2 Study Selection and Data Extraction

Studies included in this analysis were limited to animal interventions investigating the effects of flavanols (pure compounds or extracts from tea, cocoa, grape or apple), which had a control group receiving placebo or no treatment and demonstrated the improvement of one or more of the predefined cardiometabolic outcomes. Two authors independently assessed all full-text papers and in the case of disagreement, a third author was contacted. Manuscripts written in any European language were included, whereas other manuscripts were excluded. Data extraction was performed using a template. Extracted data included: publication details (authors, year of publication, ID of the publication); animal model characteristics (species, strain/model, age, gender); elements of study design (tested compound, dose used for the supplementation, duration of the intervention); cardiometabolic outcomes (type and changes in the outcome); and gene expression data (type of tissue, official gene name, official gene symbol, modulation of gene expression). The final database was cross-checked by two authors.

## 2.3 Bioinformatics analysis of gene expression data

Differentially expressed genes were submitted to Gene Set Enrichment Analysis (GSEA) using EnrichR (<https://amp.pharm.mssm.edu/Enrichr/>) to identify significantly over-represented signalling pathways (referred by the Kyoto Encyclopedia of Genes and Genomes, KEGG) that can be modulated in response to flavanol intake. Fisher's exact test with Benjamini-Hochberg correction was used to determine the significance of the enrichment results. Only pathways related to cardiometabolic health with an adjusted-p-value < 0.01 were considered. A rank score was also computed using a modification to Fisher's exact test and used to build clustergram showing the association between the input genes and the

overlapping genes of the enriched term [20]. Only pathways related to cardiometabolic health with an adjusted-p-value < 0.01 were considered. A network analysis based on these enriched terms has been rendered using Cytoscape software [21] with ClueGO associated application [22]. Transcription Factor Enrichment Analysis (TFEA) was performed using Hypergeometric Optimization of Motif EnRichment (HOMER) to identify the significant transcription factors that may explain gene expression modulation in response to flavanols [23]. TFEA was performed on down- and up-regulated gene sets separately for each tissue. Gene sets were submitted to miRwalk 3.0 (<http://mirwalk.umm.uni-heidelberg.de>) for the search of miRNA regulators using a random-forest-based statistical approach [24]. Visualization of the interactions between mRNAs, mRNA-TFs and miRNAs-targets was performed in Cytoscape software (version 3.7.1; <http://www.cytoscape.org/>) [25].

### 3. Results

#### 3.1. Description of the included studies

The process of selection applied in this systematic review is summarized in Figure 1. A total of 785 papers were initially identified in PubMed and Web of Science databases using our identified keywords. After the removal of duplicates and the first screening step by analysing the title and abstract, we used criteria defined in our search strategy to retrieve studies for the present analysis. As a consequence, 187 full-text papers were selected for data extraction. 27 papers were excluded during the detailed analysis of full text due to: the lack of relevant cardiometabolic outcome(s), analysis of gene expression restricted to the protein level, non-preclinical animal study, publication language, extracts from unexpected food source, use of animal model not relevant to cardiometabolic investigation (e.g., hepatotoxicity and surgically induced hepatic injury). Finally, significantly and differentially expressed genes at the mRNA level in response to flavanol supplementation and associated with improvement of



at least one of the predefined cardiometabolic outcomes, were extracted from 81 papers. 75 papers reported studies that had adopted a targeted approach to analyse the expression of genes (i.e., using mostly quantitative RT-PCR for a specific set of genes) in rodent models (37 in mouse, 38 in rat), whereas 6 had adopted a holistic approach using various whole genome array assays. Gene expression data obtained using a targeted approach (supplementary tables 1 and 2) have been consolidated, then submitted to bioinformatics analyses to decipher the underlying mechanisms of action by which dietary flavanols may impact on cardiometabolic health.

### **3.2. Overview of the beneficial effects of flavanols on cardiometabolic outcomes in rodent models**

Cardiometabolic outcomes assessed in the studies included in the present work are presented in supplementary tables 1 and 2. Several well established rodent models of CMD, including genetic (e.g. LDLr<sup>-/-</sup> or ApoE<sup>-/-</sup>-mice, Zucker rats) and induced CMD (e.g. chemically induced by NOS inhibitor, ouabain, angiotensin, or induced by cafeteria-, western-, high fat- or high sucrose-diets) have been employed to evaluate the impact of dietary flavanol supplementation on a large range of cardiometabolic outcomes. Acute supplementation with 250 mg/ kg BW / day (equivalent to a human equivalent dose (HED) of ~ 40 mg / kg / day in a 60 kg human) of grape seed procyanidin extract (GSPE) in healthy rats and mice decreases plasma triglycerides [26, 27], and hepatic triglycerides and cholesterol [26, 28]. Similarly, the long-term intake (between 3 to 20 weeks) of grape seeds extracts (25-1,000 mg / kg / day; HED: 4-160 mg / kg / day) [13, 29-36], tea (500-860 mg / kg / day) [13, 37-42], EGCG (50-300 mg / kg / day) [43-51] or apple flavanols extracts (0.5 % diet) [52] improves triglyceridemia [29, 32, 34, 39-41, 45, 46, 48-50], cholesterolemia [29, 32-34, 40, 46, 49, 50], plasma free fatty acids (FFAs) levels [33, 49], glycemia [34, 36, 41, 45, 46, 48, 50, 52],

insulinemia/HOMA-IR [30, 36, 40, 41, 43, 45, 46, 52], and circulating inflammatory markers (e.g. C-reactive protein (CRP)) [31], reduces hepatic cholesterol [29, 43] and triglycerides [29, 39, 43], and attenuates body weight gain [35-41, 43, 46, 48]. Similarly, procyanidin B2 at 50-150 mg / kg / day improves glucose homeostasis and decreases hepatic steatosis [53]. Catechin [54-56] and EGCG [57, 58] given at 30 mg / kg / day (HED: 2.5 mg / kg / day) and 25 mg / kg / day (HED: 2 mg / kg / day), respectively, present anti-inflammatory properties as observed by a decreased plasma level of interleukin-6 (IL-6) or tumor necrosis factor (TNF). These supplementations also preserve aorta relaxation and slow down the development of atherosclerotic lesion. EGCG (25-50 mg/kg/day for a week) also decreased systolic blood pressure and serum inflammation (CRP) in angiotensin II-induced hypertensive rats [59]. In addition, the systemic inflammation in N(G)-Nitro-L-arginine-methyl ester (L-NAME)-induced hypertensive rats is decreased by 4-week supplementation with 2-10 mg / kg / day epicatechin (HED: 0.3-16 mg / kg /day) [60]. In T2D rat models, a chronic intake of pure catechin (20 mg / kg / day; HED: 3.2 mg / kg / day) or EGCG (0.1 % in diet, that is equivalent to ~20 mg / day for a rat) reduced blood glucose [61] and improved plasma insulin level [62], respectively. All these aforementioned health effects were also observed in a large range of studies investigating the effects of flavanols supplementation on high fat diet (HFD)-induced cardiometabolic disorders [37-40, 42, 44, 46, 48, 49, 53, 63-92]. Taken together, these studies support that dietary flavanols contribute to improve cardiometabolic health in animals by reducing circulating lipids (TG, LDL-cholesterol, FFA) and their accumulation in the liver and adipose tissues, therefore preventing weight gain, and by improving glucose homeostasis.

### 3.3. Nutrigenomic impact of flavanols in cardiometabolic tissues in rodent models

A detailed analysis of studies using a targeted approach to assess the gene expression profiles retrieved a set of 110 and 77 differentially expressed genes, in response to flavanol(s) supplementation compared to the same un-supplemented diet, in cardiometabolic target tissues (liver, adipose tissues, muscle, aorta and immune cells) from mice and rats, respectively (Figure 2). Some genes were particularly investigated in identified studies (Table 1). The expression of the gene encoding the tumor necrosis factor (*Tnf*), the most investigated gene with 28 reported hits, was assessed in response to pure compounds or flavanol extracts reported here. Whatever flavanols given to animals and the target tissues assessed, *Tnf* expression is always observed as significantly decreased in comparison to the non-supplemented control [13, 37, 41, 46, 50, 52, 58, 63, 71, 72, 75, 81, 84, 92, 96, 100]. The same effect was reported for the second inflammatory marker mostly investigated i.e., interleukin-6 (*Il6*) [52, 58, 62, 63, 71, 72, 74, 78, 84, 92, 96]. The expression of the gene encoding the fatty acid synthase (*Fasn*), only measured in liver and adipose tissues, was reported to a large extent as significantly decreased in flavanol-supplemented animals [26, 29, 42, 46, 47, 64, 65, 73, 77, 80, 81, 86, 88, 90, 95]. The genes encoding for the acetyl-Coenzyme A carboxylase alpha, *Acaca* [13, 37, 46, 68, 71, 72, 77, 86] and for the transcription factor Sterol regulatory element-binding transcription factor 1 (*Srebf1*) [32, 68, 70, 73, 75, 80, 86], both involved in lipid synthesis are also significantly repressed in liver and adipose tissues. Conversely, flavanols supplementation enhance the expression of genes involved in fatty acid beta-oxidation (*Acox1*) [39, 68, 81, 82, 87, 93, 94], mitochondrial uncoupling protein 1 (*Ucp1*) [13, 39, 48, 72, 89] and the trans-membrane transport of proteins (*Abca1*) [26, 29, 47, 64, 65, 73]. Flavanol supplementation has been reported to exhibit a positive impact on the gene expression of metabolic regulators such as sirtuin 1 (*Sirt1*) [27, 46, 54, 55, 57, 71, 72] and peroxisome proliferator activated receptor (PPAR) members:

PPAR alpha (*Ppara*) [28, 43, 68, 71, 72, 75, 80, 81, 83, 93]; gamma (*Pparg*) [31, 34, 44, 59, 71, 72, 80]; and PPARg coactivator 1 alpha (*Ppargc1a*) [27, 44, 46, 48, 71, 72, 89].

### **3.4. Functional enrichment analysis of the modulated genes in response to flavanol intake**

To get a better understanding of the molecular mechanisms underlying the cardiometabolic effects associated with the intake of flavanols, the differentially expressed genes (n=110 mouse genes, n=77 rat genes) were submitted to a Gene Set Enrichment Analysis (GSEA). The enriched terms and the overlapping input genes assessed in liver and adipose tissues were rendered in clustergrams presented in Figure 3. These clustergrams revealed that the consumption of flavanols affects the expression of genes that can be clustered in four major functional groups. The first group comprises about fifteen highly significant modulated genes associated with endocrine functions (e.g. adipocytokine, glucagon and insulin signalling pathways). A second group is linked to fatty acid metabolism (e.g., PPAR signalling pathway and FFA oxidation). In the mouse liver, GSEA also revealed a third cluster related to the absorption of fatty acids (e.g. TG digestion and absorption; bile secretion, bile acid biosynthesis). The fourth group, detected in all tissues and species, comprises down-regulated genes in response to flavanol intake which are involved in inflammatory pathways (e.g., TNF-, NFκB- and toll-like receptor- signalling pathways).

The expression of mouse and rat genes was next also investigated in muscles and aortas. However, the low number of items in the gene inputs did not allow to build clustergrams following GSEA (Figure 3E). Nevertheless, the analysis showed that PPAR signalling, FA oxidation, thermogenesis, or non-alcoholic fatty liver disease (NAFLD) pathways were significantly enriched as seen in liver and adipose tissues. In murine aorta, the main target tissue in vascular diseases, the modulation of gene expression profiles affected by flavanol

intake is related to inflammatory pathways (e.g., TNF-, IL-17-, and NF- $\kappa$ B-signalling pathway), to pathways controlling endothelial activation (cell adhesion molecules and leukocyte trans-endothelial migration), and vascular tone (metabolism of arginine, a precursor for NO production).

As clustergrams further highlighted that some reported genes overlap in several enriched terms, functionally organized networks were built to better capture and summarize the relationship between genes modulated in response to flavanol intake and their enriched terms (Figure 4). In mice, the consumed flavanols mainly modulate genes involved in the interconnected pathways regulating fatty acids metabolism and glucose metabolism (insulin and glucagon regulations). In cardiometabolic rat models, flavanols modulate the pathway associated with insulin and fatty acids metabolism.

### **3.5. Putative regulators explaining the gene expression profiles in response to flavanols**

The variation in gene expression in response to the intake of flavanols may result from their action on the activity of transcription factors (TF), or an epigenetic regulation involving e.g. miRNAs and DNA methylation/histone acetylation. To explore the capabilities of flavanols to modulate transcriptional regulation, we first performed a transcription factor enrichment analysis (TFEA) by submitting our gene set to the HOMER software (Figure 5A). Secondly, we looked for miRNAs that may regulate the gene set (Figure 5B), and then searched for other regulators of the transcriptional activity (e.g., chromatin regulators) using RegulatorTrail.

TFEA aims at revealing transcription factors potentially modulated by flavanols that may explain differential gene expression profiles observed in rodent tissues (Figure 5A). This analysis was performed independently for each target tissue and rodent model. In mouse liver, the bioinformatic analysis identified TF the most likely targeted by flavanols, such as

the retinoic acid receptor (namely RXR), PPAR $\gamma$ , transcription factor MafA, and activator protein-1 (AP-1) regulating respectively 14, 13, 10 and 9 genes over the 67 genes identified as differentially expressed by flavanols. In mouse adipose tissues, flavanols appears to modulate the activity of the T-box transcription factor 5 (TBX5), the homeobox protein TG-interacting factor 1 (TGIF1) and the DNA-binding protein regulatory factor X, 6 (RFX6) that controlled the expression of 39%, 34% and 28% of the input genes, respectively. The transcription factor AP-1, the activating transcription factor 3 (ATF3) and the basic leucine zipper transcriptional factor ATF-like (BATF) appeared as the main transcriptional regulators modulated by flavanols in aorta of mice. In rat tissues, TFEA identified ATF3 and AP-1 in the liver and muscle, RUNX1 (Runt-related transcription factor 1) and HOXD13 (Homeobox protein Hox-D13) in the adipose tissue, and the transcription factor Sp5 and MAZ (Myc-associated zinc finger protein) in aorta. Taken together, these results highlight that dietary flavanols may affect the activity of a large range of TFs, and this with a tissue specificity as suggested by the low overlap between tissues of enriched TFs.

The modulation of gene expression observed in tissues of animals fed with flavanols can also be mediated by changes in miRNAs expression. From the dataset of modulated genes, the bioinformatic prediction identified 41 mouse miRNAs and 45 rat miRNAs that can be modulated in response to flavanols and affect the expression level of genes identified from publications (Figure 5B). Among the mouse miRNAs, 15 candidates may participate in the gene modulation observed in liver, 12 in adipose tissue, 9 in muscle and 12 in aorta. In rats, 22 miRNAs may modulate the gene expression profile observed in liver, 14 in adipose tissues, 11 in muscle and 2 in aorta. A very low number of predicted miRNAs overlapped between tissues, further demonstrating a tissue specific action of the flavanols.

By submitting the gene datasets to the RegulatorTrail software, some regulators other than TFs and miRNAs were identified as potential mediators in the nutrigenomic effect of

flavanols. This analysis shows that the activity of proteins altering the chromatin structure such as the helicase SMARCA4 (p-value<sub>mouse liver</sub>: 1.12e-13; p-value<sub>mouse AT</sub>: 3.96e-7; p-value<sub>rat</sub>: 6.57e-14) and the histone deacetylase HDAC3 (p-value<sub>mouse liver</sub>: 4.56e-22) may also contribute to the gene expression modulation in response to dietary flavanols. In addition, the lysine methyltransferase KMT2D known to methylate the lysine 4 position of histone H3, has been revealed as a potential epigenetic mediator of the effect of flavanols on gene expression. Another potential regulator identified is the CWC15 protein, a component of the spliceosome involved in pre-mRNA splicing (p-value<sub>mouse AT</sub>: 1.0e-7, p-value<sub>rat</sub>: 6.07e-16). All these non-transcriptional regulations may contribute to change the chromatin conformation and consequently may alter the gene expression profiles observed in response to dietary flavanols. We then performed integration of all genomic data by combined analysis of interactions between mRNA, transcription factors and miRNA targets (Figure 6). This analysis showed an inner core network, as present highest number of interactions within the mouse network, that involves the nuclear receptor PPARG, 3 miRNAs namely miR-25, miR-32, miR-363 and the protein coding gene PRDM16. In the network observed for rat data analysis, the transcription factor AP-1, miR-25, miR-92a and miR-367 constitute the major nodes of interactions.

#### 4. Discussion

The present systematic review of studies conducted in rodent models clearly highlights that dietary flavanols exert nutrigenomic effects in several target tissues involved in the development of cardiometabolic diseases. From the changes in gene expression observed, these nutrigenomic effects could largely mediate the reported beneficial effects of these compounds on a range of biomarkers associated with cardiometabolic risk. By analysing data obtained from quantitative real-time PCR, considered as the 'gold standard' method to assess gene expression, we selected 155 rodent genes (mouse + rat) as significantly

modulated in response to the consumption of dietary flavanols. The nutrigenomic response to dietary flavanols may result from a multilevel regulation involving transcriptional and non-transcriptional mediators.

The complexity of these nutrigenomic effects has been raised previously in a few animal intervention studies that have used holistic approaches [101-106]. It results from these studies that the hundreds of genes shown as modulated by dietary flavanols in several tissue targets (liver, aorta and adipose tissue) were notably involved in fatty acid metabolism, cell chemotaxis and accumulation of myeloid cells. Despite the high efficiency and performance of these holistic approaches to discriminate gene expression variation in response to a dietary intervention, the weak redundancy between these studies failed to provide enough robust and consolidated data to support further investigation of the molecular mechanisms by which dietary flavanols regulate gene expression. To overcome this limitation, we used the dataset of 155 genes identified as modulated by dietary flavanols in our systematic analysis of PCR data and submitted them to bioinformatics analyses. The functional enrichment analysis based on this gene dataset highlights that hereafter exerting a nutrigenomic effect flavanols may affect metabolism regulating several pathways involved in endocrine functions, in fatty acid metabolism and in inflammation. This result fits with the improvement of triglyceridemia, cholesterolemia, plasma FFA levels, glycemia, insulinemia and circulating inflammatory markers observed in cardiometabolic rodent models supplemented with flavanols. Several randomized controlled trials (RCT) support similar benefits of flavanols on cardiometabolic health. A meta-analysis collecting the RCTs-based evidence of the effects of flavanol-rich tea, cocoa, and apple products on biomarkers of cardiometabolic risk provides robust evidence of significant reductions in total cholesterol and triglycerides [107]. The nutrigenomic approach associated to enrichment analysis from animal studies give new



insights to understand the underlying mechanism of action that can be triggered in human in response to a nutritional intervention with flavanols.

Bioinformatic analysis (e.g., TFEA) predicts that dietary flavanols may affect the activity of a wide range of transcription factors resulting in a modulated gene expression profile. This direct transcriptional effect has been reported for different flavanol sources and compounds on transcription factors involved in different signalling pathways [108]. According to our TFEA analysis, one of the major TFs modulated appeared to be AP-1 both in rats and mice. AP-1 is made up of heterodimeric protein complexes of different protein families, including the c-Jun, c-Fos, Maf families, and it is closely related to activation transcription factor (ATF) subfamilies, some of which are defined in our study [109]. AP-1 plays a critical role in the progress of vascular dysfunction and atherogenesis [110]. Inhibition of AP-1 is one of the key targets to prevent atherosclerosis. Hexameric procyanidins isolated from cocoa protected Caco-2 cells [111] and procyanidin B2 elicited an anti-inflammatory effect in human umbilical endothelial cells through inhibition of AP-1 activation [112]. SREBP-1 is a major regulator of fatty acid synthesis, lipids, and lipoproteins. SREBP-1 may be a target transcription factor for grape seed procyanidin extract [113], EGCG [47, 114] to exert their anti-lipogenic, anti-inflammatory and hypotriglyceridemic effects in mice. Nuclear factor erythroid-2-related factor (Nrf2) controls genes encoding proteins that function in reactive oxygen species detoxification, cell survival, metabolism, inflammation, cell growth, cell adhesion, and adipocyte differentiation [115]. In cardiometabolic diseases NRF2 induces the expression of antioxidant genes, impairs atherosclerosis, reduces inflammation, modulate migration and proliferation of vascular smooth muscle cells [116]. In hepatic HepG2 cells, green tea EGCG upregulated Nrf2 dependent gene expressions of antioxidant and detoxification enzymes [115]. Similarly, cocoa phenolic extract and epicatechin upregulated antioxidant gene expressions and proteins

thus protected HepG2 cells against high glucose induced oxidative stress via Nrf2 pathway [117]. Epicatechin increased Nrf2 and its target genes in aortas of hypertensive rats resulting in lowered blood pressure, decreased oxidative stress and restored endothelial function [118]. In human aortic smooth muscle cells (HASMCs), EGCG dose dependently induced Nrf2 and inhibited IL-1 $\beta$ -induced HASMC proliferation and oxidative stress [119]. The human forkhead box (FOX) TFs are involved in multiple cellular processes such as cellular homeostasis, cell survival, cell proliferation, angiogenesis, immune regulation and cell death. In our study FOXM1 was detected in the liver of mice. FOXM1 and FOXO3a are two TFs that compete for binding to the same gene targets. FoxO3a is a major TF in cholesterol homeostasis in hepatic cells. Overexpression of FoxO3a improves hypercholesterolemia. FoxO3a deficiency leads to increased hepatic and plasma cholesterol levels. It has been shown that EGCG lowered LDL levels of rats [120]. Liver X Receptor (LXR) is an important regulator of cholesterol homeostasis and lipid metabolism. Besides it decreases the transcription of pro-inflammatory genes. In rats epicatechin decreased LXR dose dependently and improved blood lipid profile when fed high-fat diet [90]. In addition, EGCG upregulated LXR in ApoE Knock-Out mice [47]. Next to regulating TFs, flavanols have been demonstrated to modulate mRNA maturation acting on the spliceosome [121]. Thus, a large body of evidence sustains a direct effect of flavanols on transcriptional activities that can explain their nutrigenomic effects and their beneficial health effects.

Dietary polyphenols have been shown to modulate miRNAs profiles [122, 123]. miRNAs are small non-coding RNAs identified as a crucial regulatory layer in the control of transcription. Bioinformatics analysis performed suggests that flavanols may also exert a transcriptional regulation acting on the expression of miRNAs. Among the most scored miRNA is miRNA-187 that in our analysis was identified using the list of differentially expressed genes in mouse and rat models of disease in liver and adipose tissue. Interestingly,

and in agreement with our research aim, miRNA-187 is overexpressed in human subjects with T2D versus matched controls [124]. Our data reinforce the pathogenetic role for this miRNA in metabolic disease and suggest for polyphenols a complementary way of action in curbing glucose dysmetabolism. More and more data from the last years provide evidence that miRNAs have a potential to be diagnostic as well as prognostic markers for several cardiovascular diseases [125]. According to Wang et al. [126], miRNA-720, that was identified by us as potential actor in the nutrigenomic effect of flavanols in both rat and mouse, might be a useful and promising biomarker for the early detection of coronary artery disease. The downregulation of miR-150-5p (defined in mouse) has been reported as a prognostic marker for advanced heart failure [127]. In addition to regulate gene expression through a potential action on circulating miRNAs, flavanols could counteract some key actors in the onset of cardiovascular diseases.

Other molecular actors involved in the regulation of the epigenome can also participate in the nutrigenomic effects of dietary flavanols. These are proteins in charge of the modification of chromatin structure (e.g., HDAC, lysine methyltransferase, Helicase) [128]. Several studies report that an intervention with dietary flavanols modifies DNA methylation [129-131]. In cancer, epigallocatechin gallate has been shown to inhibit methyltransferase [132] and histone deacetylase activities [133] that participates to slow down cancer progression. These scientific evidence support the hypothesis that flavanols can drive transcriptional profiles through an epigenetic regulation and by consequence stress the need of new investigations to explore this further.

To exert any beneficial effects including nutrigenomic effects, flavanols need to be bioavailable. Several factors such as bioaccessibility, food matrix and also metabolizing enzymes may affect flavanol bioavailability and as consequence the bioactivity of dietary flavanols. After absorption, flavanol monomers undergo extensive phase II conjugation by

the gut microbiota and are found in the circulation in the low  $\mu\text{mol/L}$  range and as e.g., O-methylated, sulphated and glucuronidated conjugates [134]. These compounds can also be degraded into smaller phenolic compounds by the gut microbiota and thereafter absorbed [135-138]. The demonstration that circulating metabolites are responsive to the health effects of flavanols has been provided by *in vitro* studies. Claude et al. demonstrated that circulating flavanol metabolites (e.g., methylepicatechin) used in nutritionally relevant conditions preserve vascular endothelial function preventing monocyte adhesion to endothelial cells [139]. The same research group showed that these flavanol metabolites also exert nutri(epi)genomic changes in endothelial cells [140, 141] that contribute to regulate several signalling pathways already reported, as an anti-atherosclerotic effect of a flavanol supplementation [101]. These data further support that the mechanism of action of dietary flavanol monomers may be mediated by the metabolite present in the systemic circulation and that are likely to represent the physiological active forms. Moreover, our systematic analysis and integrated bioinformatic analysis of the genomic data allowed us to obtain a more precise and coherent molecular mechanisms of these molecules. In particular, we report that the potential underlying impact of the flavanols on cardiometabolic health is multi-modal and involves both transcriptional and post-transcriptional regulations

This review presents a potential complex multilevel action of dietary flavanols on gene expression contributing to health benefits. Based on observed functional modulations, flavanols are suspected to act as signal molecules, agonists or else antagonists interacting directly with proteins. In 2018, Lacroix et al. identified the polyphenol interactome and showed that polyphenols and their metabolites interact with over 5,500 proteins [142]. However, this interactome is partly built with data mining tools and only a small number of crystal structures of polyphenol-protein complexes is currently available. Other research groups used computational docking approaches to screen pertinent targets of polyphenols

metabolites that are of major importance in mediating the health effects of polyphenols [140, 143].

An increasing number of controlled clinical trials have been conducted out over the last decades to shed light on the effects of flavanol-containing products on cardiometabolic health. However, factors intrinsic to the study (design, duration, dose or products) and factors inherent to the individuals (epi-genetic, health status, age, ethnicity, gut microbiota) introduce heterogeneity in the findings [107, 144, 145]. Similarly, the weak redundancy between the animal studies does not provide us with sufficiently robust and consolidated data and therefore does not allow us to estimate the most effective doses of dietary flavanols for a given health effect. However, the identification of the main determinants in the nutrigenomic effects of the flavanols can be useful to understand the variability in response to the consumption of dietary flavanols. To this end, this review supports that *a posteriori* computational analyses of the nutrigenomic data can lend support on the identification of potential molecular mediators responsive for the bioactivity of flavanols. One critical question that still remains is related to the identification of the flavanol metabolites driving the nutrigenomic response in the target organs. Answering these pending questions will contribute to optimize the beneficial health effects of dietary bioactives.

### **Conflict of interest**

The authors have no conflict of interest.

### **Acknowledgements**

This article is based upon work from COST Action FA1403 POSITIVE (Interindividual variation in response to consumption of plant food bioactives and determinants involved) supported by COST (European Cooperation in Science and Technology; [www.cost.eu](http://www.cost.eu)). Anna

Arola-Arnal is a Serra Húnter Fellow. We are grateful to Yoan Renaud (Université Clermont Auvergne, GReD, CNRS UMR 6293, INSERM U1103, Clermont-Ferrand, France) for his support with HOMER Software.

### Funding

COST Action FA1403-European Cooperation in Science and Technology ([www.cost.eu](http://www.cost.eu)).

### Author contribution

All authors contributed to the design, data extraction and the editing of the manuscript.

### References

- [1] Arts, I. C., Hollman, P. C., Polyphenols and disease risk in epidemiologic studies. *Am J Clin Nutr* 2005, *81*, 317S-325S, 10.1093/ajcn/81.1.317S.
- [2] Xu, H., Luo, J., Huang, J., Wen, Q., Flavonoids intake and risk of type 2 diabetes mellitus: A meta-analysis of prospective cohort studies. *Medicine (Baltimore)* 2018, *97*, e0686, 10.1097/MD.0000000000010686.
- [3] Wang, X., Ouyang, Y., Liu, J., Zhu, M., Zhao, G., Bao, W., Hu, F. B., Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. *BMJ* 2014, *349*, g4490, 10.1136/bmj.g4490.
- [4] Raman, G., Avendano, E. E., Chen, S., Wang, J., Matson, J., Gayer, B., Novotny, J. A., Cassidy, A., Dietary intakes of flavan-3-ols and cardiometabolic health: systematic review and meta-analysis of randomized trials and prospective cohort studies. *Am J Clin Nutr* 2019, *110*, 1067-1078, 10.1093/ajcn/nqz178.
- [5] Cremonini, E., Fraga, C. G., Oteiza, P. I., (-)-Epicatechin in the control of glucose homeostasis: Involvement of redox-regulated mechanisms. *Free Radic Biol Med* 2019, *130*, 478-488, 10.1016/j.freeradbiomed.2018.11.010.
- [6] Oak, M. H., Auger, C., Belcastro, E., Park, S. H., Lee, H. H., Schini-Kerth, V. B., Potential mechanisms underlying cardiovascular protection by polyphenols: Role of the endothelium. *Free Radic Biol Med* 2018, *122*, 161-170, 10.1016/j.freeradbiomed.2018.03.018.
- [7] Ottaviani, J. I., Britten, A., Lucarelli, D., Luben, R., Mulligan, A. A., Lentjes, M. A., Fong, R., Gray, N., Grace, P. B., Mawson, D. H., Tym, A., Wierzbicki, A., Forouhi, N. G., Khaw, K. T., Schroeter, H.,

Kuhnle, G. G. C., Biomarker-estimated flavan-3-ol intake is associated with lower blood pressure in cross-sectional analysis in EPIC Norfolk. *Sci Rep* 2020, *10*, 17964, 10.1038/s41598-020-74863-7.

[8] Vogiatzoglou, A., Mulligan, A. A., Bhaniani, A., Lentjes, M. A. H., McTaggart, A., Luben, R. N., Heiss, C., Kelm, M., Merx, M. W., Spencer, J. P. E., Schroeter, H., Khaw, K. T., Kuhnle, G. G. C., Associations between flavan-3-ol intake and CVD risk in the Norfolk cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk). *Free Radic Biol Med* 2015, *84*, 1-10, 10.1016/j.freeradbiomed.2015.03.005.

[9] Lecour, S., Lamont, K. T., Natural polyphenols and cardioprotection. *Mini Rev Med Chem* 2011, *11*, 1191-1199, 10.2174/13895575111091191.

[10] Kamio, N., Suzuki, T., Watanabe, Y., Suhara, Y., Osakabe, N., A single oral dose of flavan-3-ols enhances energy expenditure by sympathetic nerve stimulation in mice. *Free Radic Biol Med* 2016, *91*, 256-263, 10.1016/j.freeradbiomed.2015.12.030.

[11] Matsumura, Y., Nakagawa, Y., Mikome, K., Yamamoto, H., Osakabe, N., Enhancement of energy expenditure following a single oral dose of flavan-3-ols associated with an increase in catecholamine secretion. *PLoS One* 2014, *9*, e112180, 10.1371/journal.pone.0112180.

[12] Davison, K., Howe, P. R., Potential implications of dose and diet for the effects of cocoa flavanols on cardiometabolic function. *J Agric Food Chem* 2015, *63*, 9942-9947, 10.1021/acs.jafc.5b01492.

[13] Amarowicz, R., Pegg, R. B., The Potential Protective Effects of Phenolic Compounds against Low-density Lipoprotein Oxidation. *Curr Pharm Des* 2017, *23*, 2754-2766, 10.2174/1381612823666170329142936.

[14] Steffen, Y., Schewe, T., Sies, H., Myeloperoxidase-mediated LDL oxidation and endothelial cell toxicity of oxidized LDL: attenuation by (-)-epicatechin. *Free Radic Res* 2006, *40*, 1076-1085, 10.1080/10715760600883247.

[15] Watanabe, N., Inagawa, K., Shibata, M., Osakabe, N., Flavan-3-ol fraction from cocoa powder promotes mitochondrial biogenesis in skeletal muscle in mice. *Lipids Health Dis* 2014, *13*, 64, 10.1186/1476-511X-13-64.

[16] Osakabe, N., Flavan 3-ols improve metabolic syndrome risk factors: evidence and mechanisms. *J Clin Biochem Nutr* 2013, *52*, 186-192, 10.3164/jcbtn.12-130.

[17] Sanches, J. R., Franca, L. M., Chagas, V. T., Gaspar, R. S., Dos Santos, K. A., Goncalves, L. M., Sloboda, D. M., Holloway, A. C., Dutra, R. P., Carneiro, E. M., Cappelli, A. P., Paes, A. M., Polyphenol-Rich Extract of *Syzygium cumini* Leaf Dually Improves Peripheral Insulin Sensitivity and Pancreatic Islet Function in Monosodium L-Glutamate-Induced Obese Rats. *Front Pharmacol* 2016, *7*, 48, 10.3389/fphar.2016.00048.

[18] Strat, K. M., Rowley, T. J. t., Smithson, A. T., Tessem, J. S., Hulver, M. W., Liu, D., Davy, B. M., Davy, K. P., Neilson, A. P., Mechanisms by which cocoa flavanols improve metabolic syndrome and related disorders. *J Nutr Biochem* 2016, *35*, 1-21, 10.1016/j.jnutbio.2015.12.008.

[19] Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., Group, P., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *J Clin Epidemiol* 2009, *62*, 1006-1012, 10.1016/j.jclinepi.2009.06.005.

[20] Kuleshov, M. V., Jones, M. R., Rouillard, A. D., Fernandez, N. F., Duan, Q., Wang, Z., Koplev, S., Jenkins, S. L., Jagodnik, K. M., Lachmann, A., McDermott, M. G., Monteiro, C. D., Gundersen, G. W., Ma'ayan, A., Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res* 2016, *44*, W90-97, 10.1093/nar/gkw377.

- [21] Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., Ideker, T., Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res* 2003, *13*, 2498-2504, 10.1101/gr.1239303.
- [22] Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W. H., Pages, F., Trajanoski, Z., Galon, J., ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics* 2009, *25*, 1091-1093, 10.1093/bioinformatics/btp101.
- [23] Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., Glass, C. K., Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell* 2010, *38*, 576-589, 10.1016/j.molcel.2010.05.004.
- [24] Sticht, C., De La Torre, C., Parveen, A., Gretz, N., miRWalk: An online resource for prediction of microRNA binding sites. *PLoS One* 2018, *13*, e0206239, 10.1371/journal.pone.0206239.
- [25] Su, G., Morris, J. H., Demchak, B., Bader, G. D., Biological network exploration with Cytoscape 3. *Curr Protoc Bioinformatics* 2014, *47*, 8 13 11-24, 10.1002/0471250953.bi0813s47.
- [26] Baselga-Escudero, L., Blade, C., Ribas-Latre, A., Casanova, E., Salvado, M. J., Arola, L., Arola-Arnal, A., Grape seed proanthocyanidins repress the hepatic lipid regulators miR-33 and miR-122 in rats. *Mol Nutr Food Res* 2012, *56*, 1636-1646, 10.1002/mnfr.201200237.
- [27] Pajuelo, D., Diaz, S., Quesada, H., Fernandez-Iglesias, A., Mulero, M., Arola-Arnal, A., Salvado, M. J., Blade, C., Arola, L., Acute administration of grape seed proanthocyanidin extract modulates energetic metabolism in skeletal muscle and BAT mitochondria. *J Agric Food Chem* 2011, *59*, 4279-4287, 10.1021/jf200322x.
- [28] Downing, L. E., Ferguson, B. S., Rodriguez, K., Ricketts, M. L., A grape seed procyanidin extract inhibits HDAC activity leading to increased Pparalpha phosphorylation and target-gene expression. *Mol Nutr Food Res* 2017, *61*, 10.1002/mnfr.201600347.
- [29] Baselga-Escudero, L., Blade, C., Ribas-Latre, A., Casanova, E., Salvado, M. J., Arola, L., Arola-Arnal, A., Chronic supplementation of proanthocyanidins reduces postprandial lipemia and liver miR-33a and miR-122 levels in a dose-dependent manner in healthy rats. *J Nutr Biochem* 2014, *25*, 151-156, 10.1016/j.jnutbio.2013.09.014.
- [30] Castell-Auvi, A., Cedo, L., Pallares, V., Blay, M. T., Pinent, M., Motilva, M. J., Garcia-Vallve, S., Pujadas, G., Maechler, P., Ardevol, A., Procyanidins modify insulinemia by affecting insulin production and degradation. *J Nutr Biochem* 2012, *23*, 1565-1572, 10.1016/j.jnutbio.2011.10.010.
- [31] Crescenti, A., del Bas, J. M., Arola-Arnal, A., Oms-Oliu, G., Arola, L., Caimari, A., Grape seed procyanidins administered at physiological doses to rats during pregnancy and lactation promote lipid oxidation and up-regulate AMPK in the muscle of male offspring in adulthood. *J Nutr Biochem* 2015, *26*, 912-920, 10.1016/j.jnutbio.2015.03.003.
- [32] Heidker, R. M., Caiozzi, G. C., Ricketts, M. L., Dietary procyanidins selectively modulate intestinal farnesoid X receptor-regulated gene expression to alter enterohepatic bile acid recirculation: elucidation of a novel mechanism to reduce triglyceridemia. *Mol Nutr Food Res* 2016, *60*, 727-736, 10.1002/mnfr.201500795.
- [33] Heidker, R. M., Caiozzi, G. C., Ricketts, M. L., Grape Seed Procyanidins and Cholestyramine Differentially Alter Bile Acid and Cholesterol Homeostatic Gene Expression in Mouse Intestine and Liver. *PLoS One* 2016, *11*, e0154305, 10.1371/journal.pone.0154305.
- [34] Pascual-Serrano, A., Arola-Arnal, A., Suarez-Garcia, S., Bravo, F. I., Suarez, M., Arola, L., Blade, C., Grape seed proanthocyanidin supplementation reduces adipocyte size and increases adipocyte number in obese rats. *Int J Obes (Lond)* 2017, *41*, 1246-1255, 10.1038/ijo.2017.90.



- [35] Serrano, J., Casanova-Martí, A., Gual, A., Pérez-Vendrell, A. M., Blay, M. T., Terra, X., Ardevol, A., Pinent, M., A specific dose of grape seed-derived proanthocyanidins to inhibit body weight gain limits food intake and increases energy expenditure in rats. *Eur J Nutr* 2017, *56*, 1629-1636, 10.1007/s00394-016-1209-x.
- [36] Yogalakshmi, B., Sathiya Priya, C., Anuradha, C. V., Grape seed proanthocyanidins and metformin combination attenuate hepatic endoplasmic reticulum stress in rats subjected to nutrition excess. *Arch Physiol Biochem* 2019, *125*, 174-183, 10.1080/13813455.2018.1444058.
- [37] Molina, N., Bolin, A. P., Otton, R., Green tea polyphenols change the profile of inflammatory cytokine release from lymphocytes of obese and lean rats and protect against oxidative damage. *Int Immunopharmacol* 2015, *28*, 985-996, 10.1016/j.intimp.2015.08.011.
- [38] Snoussi, C., Ducroc, R., Hamdaoui, M. H., Dhaouadi, K., Abaidi, H., Cluzeaud, F., Nazaret, C., Le Gall, M., Bado, A., Green tea decoction improves glucose tolerance and reduces weight gain of rats fed normal and high-fat diet. *J Nutr Biochem* 2014, *25*, 557-564, 10.1016/j.jnutbio.2014.01.006.
- [39] Yan, J., Zhao, Y., Zhao, B., Green tea catechins prevent obesity through modulation of peroxisome proliferator-activated receptors. *Sci China Life Sci* 2013, *56*, 804-810, 10.1007/s11427-013-4512-2.
- [40] Bae, U. J., Park, J., Park, I. W., Chae, B. M., Oh, M. R., Jung, S. J., Ryu, G. S., Chae, S. W., Park, B. H., Epigallocatechin-3-Gallate-Rich Green Tea Extract Ameliorates Fatty Liver and Weight Gain in Mice Fed a High Fat Diet by Activating the Sirtuin 1 and AMP Activating Protein Kinase Pathway. *Am J Chin Med* 2018, *46*, 617-632, 10.1142/S0192415X18500325.
- [41] Dey, P., Sasaki, G. Y., Wei, P., Li, J., Wang, L., Zhu, J., McTigue, D., Yu, Z., Bruno, R. S., Green tea extract prevents obesity in male mice by alleviating gut dysbiosis in association with improved intestinal barrier function that limits endotoxin translocation and adipose inflammation. *J Nutr Biochem* 2019, *67*, 78-89, 10.1016/j.jnutbio.2019.01.017.
- [42] Kamohara, T., Koshiguchi, M., Maeda-Yamamoto, M., Shinoda, Y., Kametani, N., Hirai, S., Egashira, Y., The Combination of 'Benifuuki' with Quercetin Suppresses Hepatic Fat Accumulation in High-Fat High-Cholesterol Diet-Fed Rats. *J Nutr Sci Vitaminol (Tokyo)* 2019, *65*, 196-201, 10.3177/jnsv.65.196.
- [43] Huang, J., Feng, S., Liu, A., Dai, Z., Wang, H., Reuhl, K., Lu, W., Yang, C. S., Green Tea Polyphenol EGCG Alleviates Metabolic Abnormality and Fatty Liver by Decreasing Bile Acid and Lipid Absorption in Mice. *Mol Nutr Food Res* 2018, *62*, 10.1002/mnfr.201700696.
- [44] Li, F., Gao, C., Yan, P., Zhang, M., Wang, Y., Hu, Y., Wu, X., Wang, X., Sheng, J., EGCG Reduces Obesity and White Adipose Tissue Gain Partly Through AMPK Activation in Mice. *Front Pharmacol* 2018, *9*, 1366, 10.3389/fphar.2018.01366.
- [45] Li, X., Li, S., Chen, M., Wang, J., Xie, B., Sun, Z., (-)-Epigallocatechin-3-gallate (EGCG) inhibits starch digestion and improves glucose homeostasis through direct or indirect activation of PXR/CAR-mediated phase II metabolism in diabetic mice. *Food Funct* 2018, *9*, 4651-4663, 10.1039/c8fo01293h.
- [46] Mi, Y., Qi, G., Fan, R., Ji, X., Liu, Z., Liu, X., EGCG ameliorates diet-induced metabolic syndrome associating with the circadian clock. *Biochim Biophys Acta Mol Basis Dis* 2017, *1863*, 1575-1589, 10.1016/j.bbdis.2017.04.009.
- [47] Wang, W., Zhang, Z. Z., Wu, Y., Wang, R. Q., Chen, J. W., Chen, J., Zhang, Y., Chen, Y. J., Geng, M., Xu, Z. D., Dai, M., Li, J. H., Pan, L. L., (-)-Epigallocatechin-3-Gallate Ameliorates Atherosclerosis and Modulates Hepatic Lipid Metabolic Gene Expression in Apolipoprotein E Knockout Mice: Involvement of TTC39B. *Front Pharmacol* 2018, *9*, 195, 10.3389/fphar.2018.00195.

[48] Zhou, J., Mao, L., Xu, P., Wang, Y., Effects of (-)-Epigallocatechin Gallate (EGCG) on Energy Expenditure and Microglia-Mediated Hypothalamic Inflammation in Mice Fed a High-Fat Diet. *Nutrients* 2018, *10*, 1681, 10.3390/nu10111681.

[49] Li, Y., Wu, S., Epigallocatechin gallate suppresses hepatic cholesterol synthesis by targeting SREBP-2 through SIRT1/FOXO1 signaling pathway. *Mol Cell Biochem* 2018, *448*, 175-185, 10.1007/s11010-018-3324-x.

[50] Muhammed, I., Sankar, S., Govindaraj, S., Ameliorative Effect of Epigallocatechin Gallate on Cardiac Hypertrophy and Fibrosis in Aged Rats. *J Cardiovasc Pharmacol* 2018, *71*, 65-75, 10.1097/FJC.0000000000000545.

[51] Zhang, Q., Hu, L., Chen, L., Li, H., Wu, J., Liu, W., Zhang, M., Yan, G., (-)-Epigallocatechin-3-gallate, the major green tea catechin, regulates the desensitization of beta1 adrenoceptor via GRK2 in experimental heart failure. *Inflammopharmacology* 2018, *26*, 1081-1091, 10.1007/s10787-017-0429-x.

[52] Ogura, K., Ogura, M., Shoji, T., Sato, Y., Tahara, Y., Yamano, G., Sato, H., Sugizaki, K., Fujita, N., Tatsuoka, H., Usui, R., Mukai, E., Fujimoto, S., Inagaki, N., Nagashima, K., Oral Administration of Apple Procyanidins Ameliorates Insulin Resistance via Suppression of Pro-Inflammatory Cytokine Expression in Liver of Diabetic ob/ob Mice. *J Agric Food Chem* 2016, *64*, 8857-8865, 10.1021/acs.jafc.6b03424.

[53] Su, H., Li, Y., Hu, D., Xie, L., Ke, H., Zheng, X., Chen, W., Procyanidin B2 ameliorates free fatty acids-induced hepatic steatosis through regulating TFEB-mediated lysosomal pathway and redox state. *Free Radic Biol Med* 2018, *126*, 269-286, 10.1016/j.freeradbiomed.2018.08.024.

[54] Gendron, M. E., Theoret, J. F., Mamarbachi, A. M., Drouin, A., Nguyen, A., Bolduc, V., Thorin-Trescases, N., Merhi, Y., Thorin, E., Late chronic catechin antioxidant treatment is deleterious to the endothelial function in aging mice with established atherosclerosis. *Am J Physiol Heart Circ Physiol* 2010, *298*, H2062-2070, 10.1152/ajpheart.00532.2009.

[55] Gendron, M. E., Thorin-Trescases, N., Mamarbachi, A. M., Villeneuve, L., Theoret, J. F., Mehri, Y., Thorin, E., Time-dependent beneficial effect of chronic polyphenol treatment with catechin on endothelial dysfunction in aging mice. *Dose Response* 2012, *10*, 108-119, 10.2203/dose-response.11-014.Thorin.

[56] Leblond, F., Nguyen, A., Bolduc, V., Lambert, J., Yu, C., Duquette, N., Thorin, E., Postnatal exposure to voluntary exercise but not the antioxidant catechin protects the vasculature after a switch to an atherogenic environment in middle-age mice. *Pflugers Arch* 2013, *465*, 197-208, 10.1007/s00424-012-1206-8.

[57] Liu, H. W., Chan, Y. C., Wang, M. F., Wei, C. C., Chang, S. J., Dietary (-)-Epigallocatechin-3-gallate Supplementation Counteracts Aging-Associated Skeletal Muscle Insulin Resistance and Fatty Liver in Senescence-Accelerated Mouse. *J Agric Food Chem* 2015, *63*, 8407-8417, 10.1021/acs.jafc.5b02501.

[58] Niu, Y., Na, L., Feng, R., Gong, L., Zhao, Y., Li, Q., Li, Y., Sun, C., The phytochemical, EGCG, extends lifespan by reducing liver and kidney function damage and improving age-associated inflammation and oxidative stress in healthy rats. *Aging Cell* 2013, *12*, 1041-1049, 10.1111/acel.12133.

[59] Zhao, J., Liu, J., Pang, X., Zhang, X., Wang, S., Wu, D., Epigallocatechin-3-gallate inhibits angiotensin II-induced C-reactive protein generation through interfering with the AT1-ROS-ERK1/2 signaling pathway in hepatocytes. *Naunyn Schmiedebergs Arch Pharmacol* 2016, *389*, 1225-1234, 10.1007/s00210-016-1279-6.

[60] Gomez-Guzman, M., Jimenez, R., Sanchez, M., Romero, M., O'Valle, F., Lopez-Sepulveda, R., Quintela, A. M., Galindo, P., Zarzuelo, M. J., Bailon, E., Delpon, E., Perez-Vizcaino, F., Duarte, J.,

Chronic (-)-epicatechin improves vascular oxidative and inflammatory status but not hypertension in chronic nitric oxide-deficient rats. *Br J Nutr* 2011, *106*, 1337-1348, 10.1017/S0007114511004314.

[61] Daisy, P., Balasubramanian, K., Rajalakshmi, M., Eliza, J., Selvaraj, J., Insulin mimetic impact of Catechin isolated from *Cassia fistula* on the glucose oxidation and molecular mechanisms of glucose uptake on Streptozotocin-induced diabetic Wistar rats. *Phytomedicine* 2010, *17*, 28-36, 10.1016/j.phymed.2009.10.018.

[62] Uchiyama, Y., Suzuki, T., Mochizuki, K., Goda, T., Dietary supplementation with a low dose of (-)-epigallocatechin-3-gallate reduces pro-inflammatory responses in peripheral leukocytes of non-obese type 2 diabetic GK rats. *J Nutr Sci Vitaminol (Tokyo)* 2013, *59*, 541-547, 10.3177/jnsv.59.541.

[63] Bao, S., Cao, Y., Fan, C., Fan, Y., Bai, S., Teng, W., Shan, Z., Epigallocatechin gallate improves insulin signaling by decreasing toll-like receptor 4 (TLR4) activity in adipose tissues of high-fat diet rats. *Mol Nutr Food Res* 2014, *58*, 677-686, 10.1002/mnfr.201300335.

[64] Baselga-Escudero, L., Arola-Arnal, A., Pascual-Serrano, A., Ribas-Latre, A., Casanova, E., Salvado, M. J., Arola, L., Blade, C., Chronic administration of proanthocyanidins or docosahexaenoic acid reverses the increase of miR-33a and miR-122 in dyslipidemic obese rats. *PLoS One* 2013, *8*, e69817, 10.1371/journal.pone.0069817.

[65] Baselga-Escudero, L., Pascual-Serrano, A., Ribas-Latre, A., Casanova, E., Salvado, M. J., Arola, L., Arola-Arnal, A., Blade, C., Long-term supplementation with a low dose of proanthocyanidins normalized liver miR-33a and miR-122 levels in high-fat diet-induced obese rats. *Nutr Res* 2015, *35*, 337-345, 10.1016/j.nutres.2015.02.008.

[66] Bettaieb, A., Vazquez Prieto, M. A., Rodriguez Lanzi, C., Miatello, R. M., Haj, F. G., Fraga, C. G., Oteiza, P. I., (-)-Epicatechin mitigates high-fructose-associated insulin resistance by modulating redox signaling and endoplasmic reticulum stress. *Free Radic Biol Med* 2014, *72*, 247-256, 10.1016/j.freeradbiomed.2014.04.011.

[67] Casanova, E., Baselga-Escudero, L., Ribas-Latre, A., Cedo, L., Arola-Arnal, A., Pinent, M., Blade, C., Arola, L., Salvado, M. J., Chronic intake of proanthocyanidins and docosahexaenoic acid improves skeletal muscle oxidative capacity in diet-obese rats. *J Nutr Biochem* 2014, *25*, 1003-1010, 10.1016/j.jnutbio.2014.05.003.

[68] Chen, N., Bezzina, R., Hinch, E., Lewandowski, P. A., Cameron-Smith, D., Mathai, M. L., Jois, M., Sinclair, A. J., Begg, D. P., Wark, J. D., Weisinger, H. S., Weisinger, R. S., Green tea, black tea, and epigallocatechin modify body composition, improve glucose tolerance, and differentially alter metabolic gene expression in rats fed a high-fat diet. *Nutr Res* 2009, *29*, 784-793, 10.1016/j.nutres.2009.10.003.

[69] Park, H. J., Lee, J. Y., Chung, M. Y., Park, Y. K., Bower, A. M., Koo, S. I., Giardina, C., Bruno, R. S., Green tea extract suppresses NFkappaB activation and inflammatory responses in diet-induced obese rats with nonalcoholic steatohepatitis. *J Nutr* 2012, *142*, 57-63, 10.3945/jn.111.148544.

[70] Quesada, H., del Bas, J. M., Pajuelo, D., Diaz, S., Fernandez-Larrea, J., Pinent, M., Arola, L., Salvado, M. J., Blade, C., Grape seed proanthocyanidins correct dyslipidemia associated with a high-fat diet in rats and repress genes controlling lipogenesis and VLDL assembling in liver. *Int J Obes (Lond)* 2009, *33*, 1007-1012, 10.1038/ijo.2009.136.

[71] Rabadan-Chavez, G. M., Miliar Garcia, A., Paniagua Catro, N., Escalona Cardoso, G., Reyes-Maldonado, E., Jaramillo-Flores, M. E., Modulating the expression of genes associated with hepatic lipid metabolism, lipoperoxidation and inflammation by cocoa, cocoa extract and cocoa flavanols related to hepatic steatosis induced by a hypercaloric diet. *Food Res Int* 2016, *89*, 937-945, <https://doi.org/10.1016/j.foodres.2016.03.019>.

- [72] Rabadan-Chavez, G. M., Quevedo-Corona, L., Miliar Garcia, A., Reyes-Maldonado, E., Jaramillo-Flores, M. E., Cocoa powder, cocoa extract and epicatechin attenuate hypercaloric diet-induced obesity through enhanced  $\beta$ -oxidation and energy expenditure in white adipose tissue. *Journal of Functional Foods* 2016, 20, 54-67.
- [73] Shrestha, S., Ehlers, S. J., Lee, J. Y., Fernandez, M. L., Koo, S. I., Dietary green tea extract lowers plasma and hepatic triglycerides and decreases the expression of sterol regulatory element-binding protein-1c mRNA and its responsive genes in fructose-fed, ovariectomized rats. *J Nutr* 2009, 139, 640-645, 10.3945/jn.108.103341.
- [74] Terra, X., Montagut, G., Bustos, M., Llopiz, N., Ardevol, A., Blade, C., Fernandez-Larrea, J., Pujadas, G., Salvado, J., Arola, L., Blay, M., Grape-seed procyanidins prevent low-grade inflammation by modulating cytokine expression in rats fed a high-fat diet. *J Nutr Biochem* 2009, 20, 210-218, 10.1016/j.jnutbio.2008.02.005.
- [75] Yogalakshmi, B., Sreeja, S., Geetha, R., Radika, M. K., Anuradha, C. V., Grape seed proanthocyanidin rescues rats from steatosis: a comparative and combination study with metformin. *J Lipids* 2013, 2013, 153897, 10.1155/2013/153897.
- [76] Cai, Y., Kurita-Ochiai, T., Hashizume, T., Yamamoto, M., Green tea epigallocatechin-3-gallate attenuates Porphyromonas gingivalis-induced atherosclerosis. *Pathog Dis* 2013, 67, 76-83, 10.1111/2049-632X.12001.
- [77] Friedrich, M., Petzke, K. J., Raederstorff, D., Wolfram, S., Klaus, S., Acute effects of epigallocatechin gallate from green tea on oxidation and tissue incorporation of dietary lipids in mice fed a high-fat diet. *Int J Obes (Lond)* 2012, 36, 735-743, 10.1038/ijo.2011.136.
- [78] Gu, Y., Yu, S., Lambert, J. D., Dietary cocoa ameliorates obesity-related inflammation in high fat-fed mice. *Eur J Nutr* 2014, 53, 149-158, 10.1007/s00394-013-0510-1.
- [79] Hoek-van den Hil, E. F., van Schothorst, E. M., van der Stelt, I., Swarts, H. J., van Vliet, M., Amolo, T., Vervoort, J. J., Venema, D., Hollman, P. C., Rietjens, I. M., Keijer, J., Direct comparison of metabolic health effects of the flavonoids quercetin, hesperetin, epicatechin, apigenin and anthocyanins in high-fat-diet-fed mice. *Genes Nutr* 2015, 10, 469, 10.1007/s12263-015-0469-z.
- [80] Lee, M. S., Kim, C. T., Kim, Y., Green tea (-)-epigallocatechin-3-gallate reduces body weight with regulation of multiple genes expression in adipose tissue of diet-induced obese mice. *Ann Nutr Metab* 2009, 54, 151-157, 10.1159/000214834.
- [81] Masumoto, S., Terao, A., Yamamoto, Y., Mukai, T., Miura, T., Shoji, T., Non-absorbable apple procyanidins prevent obesity associated with gut microbial and metabolomic changes. *Sci Rep* 2016, 6, 31208, 10.1038/srep31208.
- [82] Murase, T., Nagasawa, A., Suzuki, J., Hase, T., Tokimitsu, I., Beneficial effects of tea catechins on diet-induced obesity: stimulation of lipid catabolism in the liver. *Int J Obes Relat Metab Disord* 2002, 26, 1459-1464, 10.1038/sj.ijo.0802141.
- [83] Sae-Tan, S., Grove, K. A., Kennett, M. J., Lambert, J. D., (-)-Epigallocatechin-3-gallate increases the expression of genes related to fat oxidation in the skeletal muscle of high fat-fed mice. *Food Funct* 2011, 2, 111-116, 10.1039/c0fo00155d.
- [84] Sano, T., Nagayasu, S., Suzuki, S., Iwashita, M., Yamashita, A., Shinjo, T., Sanui, T., Kushiya, A., Kanematsu, T., Asano, T., Nishimura, F., Epicatechin downregulates adipose tissue CCL19 expression and thereby ameliorates diet-induced obesity and insulin resistance. *Nutr Metab Cardiovasc Dis* 2017, 27, 249-259, 10.1016/j.numecd.2016.11.008.
- [85] Shimamura, Y., Yoda, M., Sakakibara, H., Matsunaga, K., Masuda, S., Pu-erh tea suppresses diet-induced body fat accumulation in C57BL/6J mice by down-regulating SREBP-1c and related molecules. *Biosci Biotechnol Biochem* 2013, 77, 1455-1460, 10.1271/bbb.130097.

- [86] Suzuki, T., Kumazoe, M., Kim, Y., Yamashita, S., Nakahara, K., Tsukamoto, S., Sasaki, M., Hagihara, T., Tsurudome, Y., Huang, Y., Maeda-Yamamoto, M., Shinoda, Y., Yamaguchi, W., Yamada, K., Tachibana, H., Green tea extract containing a highly absorbent catechin prevents diet-induced lipid metabolism disorder. *Sci Rep* 2013, 3, 2749, 10.1038/srep02749.
- [87] Wolfram, S., Raederstorff, D., Preller, M., Wang, Y., Teixeira, S. R., Riegger, C., Weber, P., Epigallocatechin gallate supplementation alleviates diabetes in rodents. *J Nutr* 2006, 136, 2512-2518, 10.1093/jn/136.10.2512.
- [88] Wolfram, S., Raederstorff, D., Wang, Y., Teixeira, S. R., Elste, V., Weber, P., TEAVIGO (epigallocatechin gallate) supplementation prevents obesity in rodents by reducing adipose tissue mass. *Ann Nutr Metab* 2005, 49, 54-63, 10.1159/000084178.
- [89] Yamashita, Y., Okabe, M., Natsume, M., Ashida, H., Prevention mechanisms of glucose intolerance and obesity by cacao liquor procyanidin extract in high-fat diet-fed C57BL/6 mice. *Arch Biochem Biophys* 2012, 527, 95-104, 10.1016/j.abb.2012.03.018.
- [90] Cheng, H., Xu, N., Zhao, W., Su, J., Liang, M., Xie, Z., Wu, X., Li, Q., (-)-Epicatechin regulates blood lipids and attenuates hepatic steatosis in rats fed high-fat diet. *Mol Nutr Food Res* 2017, 61, 10.1002/mnfr.201700303.
- [91] Sankar, J., Rathinavel, A., Mohammed Sadullah, S. S., Devaraj, S. N., Oligomeric proanthocyanidins mitigate cholesterol and cholic acid diet-induced hepatic dysfunction in male Sprague Dawley rats. *J Biochem Mol Toxicol* 2018, e22234, 10.1002/jbt.22234.
- [92] Tu, S., Xiao, F., Min, X., Chen, H., Fan, X., Cao, K., Catechin Attenuates Coronary Heart Disease in a Rat Model by Inhibiting Inflammation. *Cardiovasc Toxicol* 2018, 18, 393-399, 10.1007/s12012-018-9449-z.
- [93] Sae-Tan, S., Rogers, C. J., Lambert, J. D., Voluntary exercise and green tea enhance the expression of genes related to energy utilization and attenuate metabolic syndrome in high fat fed mice. *Mol Nutr Food Res* 2014, 58, 1156-1159, 10.1002/mnfr.201300621.
- [94] Fidaleo, M., Fracassi, A., Zuurro, A., Lavecchia, R., Moreno, S., Sartori, C., Cocoa protective effects against abnormal fat storage and oxidative stress induced by a high-fat diet involve PPARalpha signalling activation. *Food Funct* 2014, 5, 2931-2939, 10.1039/c4fo00616j.
- [95] Sun, X., Yamasaki, M., Katsube, T., Shiwaku, K., Effects of quercetin derivatives from mulberry leaves: Improved gene expression related hepatic lipid and glucose metabolism in short-term high-fat fed mice. *Nutr Res Pract* 2015, 9, 137-143, 10.4162/nrp.2015.9.2.137.
- [96] Noll, C., Lameth, J., Paul, J. L., Janel, N., Effect of catechin/epicatechin dietary intake on endothelial dysfunction biomarkers and proinflammatory cytokines in aorta of hyperhomocysteinemic mice. *Eur J Nutr* 2013, 52, 1243-1250, 10.1007/s00394-012-0435-0.
- [97] Dong, Z. X., Wan, L., Wang, R. J., Shi, Y. Q., Liu, G. Z., Zheng, S. J., Hou, H. L., Han, W., Hai, X., (-)-Epicatechin Suppresses Angiotensin II-induced Cardiac Hypertrophy via the Activation of the SP1/SIRT1 Signaling Pathway. *Cell Physiol Biochem* 2017, 41, 2004-2015, 10.1159/000475396.
- [98] Zhao, Y., Yang, L., Huang, Z., Lin, L., Zheng, G., Synergistic effects of caffeine and catechins on lipid metabolism in chronically fed mice via the AMP-activated protein kinase signaling pathway. *Eur J Nutr* 2017, 56, 2309-2318, 10.1007/s00394-016-1271-4.
- [99] Liu, X., Qiu, J., Zhao, S., You, B., Ji, X., Wang, Y., Cui, X., Wang, Q., Gao, H., Grape seed proanthocyanidin extract alleviates ouabain-induced vascular remodeling through regulation of endothelial function. *Mol Med Rep* 2012, 6, 949-954, 10.3892/mmr.2012.1026.

- [100] Setozaki, S., Minakata, K., Masumoto, H., Hirao, S., Yamazaki, K., Kuwahara, K., Ikeda, T., Sakata, R., Prevention of abdominal aortic aneurysm progression by oral administration of green tea polyphenol in a rat model. *J Vasc Surg* 2017, *65*, 1803-1812 e1802, 10.1016/j.jvs.2016.06.003.
- [101] Auclair, S., Milenkovic, D., Besson, C., Chauvet, S., Gueux, E., Morand, C., Mazur, A., Scalbert, A., Catechin reduces atherosclerotic lesion development in apo E-deficient mice: a transcriptomic study. *Atherosclerosis* 2009, *204*, e21-27, 10.1016/j.atherosclerosis.2008.12.007.
- [102] del Bas, J. M., Crescenti, A., Arola-Arnal, A., Oms-Oliu, G., Arola, L., Caimari, A., Grape seed procyanidin supplementation to rats fed a high-fat diet during pregnancy and lactation increases the body fat content and modulates the inflammatory response and the adipose tissue metabolism of the male offspring in youth. *Int J Obes (Lond)* 2015, *39*, 7-15, 10.1038/ijo.2014.159.
- [103] Del Bas, J. M., Ricketts, M. L., Vaque, M., Sala, E., Quesada, H., Ardevol, A., Salvado, M. J., Blay, M., Arola, L., Moore, D. D., Pujadas, G., Fernandez-Larrea, J., Blade, C., Dietary procyanidins enhance transcriptional activity of bile acid-activated FXR in vitro and reduce triglyceridemia in vivo in a FXR-dependent manner. *Mol Nutr Food Res* 2009, *53*, 805-814, 10.1002/mnfr.200800364.
- [104] Lu, C., Zhu, W., Shen, C. L., Gao, W., Green tea polyphenols reduce body weight in rats by modulating obesity-related genes. *PLoS One* 2012, *7*, e38332, 10.1371/journal.pone.0038332.
- [105] Meng, Q., Velalar, C. N., Ruan, R., Regulating the age-related oxidative damage, mitochondrial integrity, and antioxidative enzyme activity in Fischer 344 rats by supplementation of the antioxidant epigallocatechin-3-gallate. *Rejuvenation Res* 2008, *11*, 649-660, 10.1089/rej.2007.0645.
- [106] Morrison, M., van der Heijden, R., Heeringa, P., Kaijzel, E., Verschuren, L., Blomhoff, R., Kooistra, T., Kleemann, R., Epicatechin attenuates atherosclerosis and exerts anti-inflammatory effects on diet-induced human-CRP and NFkappaB in vivo. *Atherosclerosis* 2014, *233*, 149-156, 10.1016/j.atherosclerosis.2013.12.027.
- [107] González-Sarrías, A., Combet, E., Pinto, P., Mena, P., Dall'Asta, M., Garcia-Aloy, M., Rodríguez-Mateos, A., Gibney, E. R., Dumont, J., Massaro, M., Sánchez-Meca, J., Morand, C., García-Cones, M.-T., A Systematic Review and Meta-Analysis of the Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy. *Nutrients* 2017, *9*, 746, 10.3390/nu9070746
- [108] Park, S., Polyphenol Compound as a Transcription Factor Inhibitor. *Nutrients* 2015, *7*, 8987-9004, 10.3390/nu7115445.
- [109] Shaulian, E., Karin, M., AP-1 as a regulator of cell life and death. *Nat Cell Biol* 2002, *4*, E131-136, 10.1038/ncb0502-e131.
- [110] Meijer, C. A., Le Haen, P. A., van Dijk, R. A., Hira, M., Hamming, J. F., van Bockel, J. H., Lindeman, J. H., Activator protein-1 (AP-1) signalling in human atherosclerosis: results of a systematic evaluation and intervention study. *Clin Sci (Lond)* 2012, *122*, 421-428, 10.1042/CS20110234.
- [111] Da Silva, M., Jagggers, G. K., Verstraeten, S. V., Erlejman, A. G., Fraga, C. G., Oteiza, P. I., Large procyanidins prevent bile-acid-induced oxidant production and membrane-initiated ERK1/2, p38, and Akt activation in Caco-2 cells. *Free Radic Biol Med* 2012, *52*, 151-159, 10.1016/j.freeradbiomed.2011.10.436.
- [112] Yang, H., Xiao, L., Yuan, Y., Luo, X., Jiang, M., Ni, J., Wang, N., Procyanidin B2 inhibits NLRP3 inflammasome activation in human vascular endothelial cells. *Biochem Pharmacol* 2014, *92*, 599-606, 10.1016/j.bcp.2014.10.001.
- [113] Del Bas, J. M., Ricketts, M. L., Baiges, I., Quesada, H., Ardevol, A., Salvado, M. J., Pujadas, G., Blay, M., Arola, L., Blade, C., Moore, D. D., Fernandez-Larrea, J., Dietary procyanidins lower

triglyceride levels signaling through the nuclear receptor small heterodimer partner. *Mol Nutr Food Res* 2008, *52*, 1172-1181, 10.1002/mnfr.200800054.

[114] Liu, H. W., Wei, C. C., Chen, Y. J., Chen, Y. A., Chang, S. J., Flavanol-rich lychee fruit extract alleviates diet-induced insulin resistance via suppressing mTOR/SREBP-1 mediated lipogenesis in liver and restoring insulin signaling in skeletal muscle. *Mol Nutr Food Res* 2016, *60*, 2288-2296, 10.1002/mnfr.201501064.

[115] Na, H. K., Surh, Y. J., Modulation of Nrf2-mediated antioxidant and detoxifying enzyme induction by the green tea polyphenol EGCG. *Food Chem Toxicol* 2008, *46*, 1271-1278, 10.1016/j.fct.2007.10.006.

[116] da Costa, R. M., Rodrigues, D., Pereira, C. A., Silva, J. F., Alves, J. V., Lobato, N. S., Tostes, R. C., Nrf2 as a Potential Mediator of Cardiovascular Risk in Metabolic Diseases. *Front Pharmacol* 2019, *10*, 382, 10.3389/fphar.2019.00382.

[117] Cordero-Herrera, I., Martin, M. A., Goya, L., Ramos, S., Cocoa flavonoids protect hepatic cells against high-glucose-induced oxidative stress: relevance of MAPKs. *Mol Nutr Food Res* 2015, *59*, 597-609, 10.1002/mnfr.201400492.

[118] Gomez-Guzman, M., Jimenez, R., Sanchez, M., Zarzuelo, M. J., Galindo, P., Quintela, A. M., Lopez-Sepulveda, R., Romero, M., Tamargo, J., Vargas, F., Perez-Vizcaino, F., Duarte, J., Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension. *Free Radic Biol Med* 2012, *52*, 70-79, 10.1016/j.freeradbiomed.2011.09.015.

[119] Liu, P. L., Liu, J. T., Kuo, H. F., Chong, I. W., Hsieh, C. C., Epigallocatechin gallate attenuates proliferation and oxidative stress in human vascular smooth muscle cells induced by interleukin-1beta via heme oxygenase-1. *Mediators Inflamm* 2014, *2014*, 523684, 10.1155/2014/523684.

[120] Cui, C. J., Jin, J. L., Guo, L. N., Sun, J., Wu, N. Q., Guo, Y. L., Liu, G., Dong, Q., Li, J. J., Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1alpha and activating FoxO3a. *J Transl Med* 2020, *18*, 195, 10.1186/s12967-020-02362-4.

[121] Manna, S., Banerjee, S., Saha, P., Roy, A., Das, S., Panda, C. K., Differential alterations in metabolic pattern of the spliceosomal UsnRNAs during pre-malignant lung lesions induced by benzo(a)pyrene: modulation by tea polyphenols. *Mol Cell Biochem* 2006, *289*, 149-157, 10.1007/s11010-006-9158-y.

[122] Milenkovic, D., Deval, C., Gouranton, E., Landrier, J. F., Scalbert, A., Morand, C., Mazur, A., Modulation of miRNA expression by dietary polyphenols in apoE deficient mice: a new mechanism of the action of polyphenols. *PLoS One* 2012, *7*, e29837, 10.1371/journal.pone.0029837.

[123] Milenkovic, D., Jude, B., Morand, C., miRNA as molecular target of polyphenols underlying their biological effects. *Free Radic Biol Med* 2013, *64*, 40-51, 10.1016/j.freeradbiomed.2013.05.046.

[124] Locke, J. M., da Silva Xavier, G., Dawe, H. R., Rutter, G. A., Harries, L. W., Increased expression of miR-187 in human islets from individuals with type 2 diabetes is associated with reduced glucose-stimulated insulin secretion. *Diabetologia* 2014, *57*, 122-128, 10.1007/s00125-013-3089-4.

[125] Schulte, C., Karakas, M., Zeller, T., microRNAs in cardiovascular disease - clinical application. *Clin Chem Lab Med* 2017, *55*, 687-704, 10.1515/cclm-2016-0576.

[126] Wang, H. W., Huang, T. S., Lo, H. H., Huang, P. H., Lin, C. C., Chang, S. J., Liao, K. H., Tsai, C. H., Chan, C. H., Tsai, C. F., Cheng, Y. C., Chiu, Y. L., Tsai, T. N., Cheng, C. C., Cheng, S. M., Deficiency of the microRNA-31-microRNA-720 pathway in the plasma and endothelial progenitor cells from patients with coronary artery disease. *Arterioscler Thromb Vasc Biol* 2014, *34*, 857-869, 10.1161/ATVBAHA.113.303001.

- [127] Scrutinio, D., Conserva, F., Passantino, A., Iacoviello, M., Lagioia, R., Gesualdo, L., Circulating microRNA-150-5p as a novel biomarker for advanced heart failure: A genome-wide prospective study. *J Heart Lung Transplant* 2017, *36*, 616-624, 10.1016/j.healun.2017.02.008.
- [128] Arora, I., Sharma, M., Tollefsbol, T. O., Combinatorial Epigenetics Impact of Polyphenols and Phytochemicals in Cancer Prevention and Therapy. *Int J Mol Sci* 2019, *20*, 10.3390/ijms20184567.
- [129] Rahman, I., Chung, S., Dietary polyphenols, deacetylases and chromatin remodeling in inflammation. *J Nutrigenet Nutrigenomics* 2010, *3*, 220-230, 10.1159/000324358.
- [130] Sae-Lee, C., Corsi, S., Barrow, T. M., Kuhnle, G. G. C., Bollati, V., Mathers, J. C., Byun, H. M., Dietary Intervention Modifies DNA Methylation Age Assessed by the Epigenetic Clock. *Mol Nutr Food Res* 2018, *62*, e1800092, 10.1002/mnfr.201800092.
- [131] Yiannakopoulou, E. C., Targeting DNA methylation with green tea catechins. *Pharmacology* 2015, *95*, 111-116, 10.1159/000375503.
- [132] Sheng, J., Shi, W., Guo, H., Long, W., Wang, Y., Qi, J., Liu, J., Xu, Y., The Inhibitory Effect of (-)-Epigallocatechin-3-Gallate on Breast Cancer Progression via Reducing SCUBE2 Methylation and DNMT Activity. *Molecules* 2019, *24*, 10.3390/molecules24162899.
- [133] Khan, M. A., Hussain, A., Sundaram, M. K., Alalami, U., Gunasekera, D., Ramesh, L., Hamza, A., Quraishi, U., (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells. *Oncol Rep* 2015, *33*, 1976-1984, 10.3892/or.2015.3802.
- [134] Borges, G., Ottaviani, J. I., van der Hooft, J. J. J., Schroeter, H., Crozier, A., Absorption, metabolism, distribution and excretion of (-)-epicatechin: A review of recent findings. *Mol Aspects Med* 2018, *61*, 18-30, 10.1016/j.mam.2017.11.002.
- [135] Kahle, K., Huemmer, W., Kempf, M., Scheppach, W., Erk, T., Richling, E., Polyphenols are intensively metabolized in the human gastrointestinal tract after apple juice consumption. *J Agric Food Chem* 2007, *55*, 10605-10614, 10.1021/jf071942r.
- [136] Kahle, K., Kempf, M., Schreier, P., Scheppach, W., Schrenk, D., Kautenburger, T., Hecker, D., Huemmer, W., Ackermann, M., Richling, E., Intestinal transit and systemic metabolism of apple polyphenols. *Eur J Nutr* 2011, *50*, 507-522, 10.1007/s00394-010-0157-0.
- [137] Murota, K., Nakamura, Y., Uehara, M., Flavonoid metabolism: the interaction of metabolites and gut microbiota. *Biosci Biotechnol Biochem* 2018, *82*, 600-610, 10.1080/09168451.2018.1444467.
- [138] Ottaviani, J. I., Borges, G., Momma, T. Y., Spencer, J. P., Keen, C. L., Crozier, A., Schroeter, H., The metabolome of [2-(14)C](-)-epicatechin in humans: implications for the assessment of efficacy, safety, and mechanisms of action of polyphenolic bioactives. *Sci Rep* 2016, *6*, 29034, 10.1038/srep29034.
- [139] Claude, S., Boby, C., Rodriguez-Mateos, A., Spencer, J. P., Gerard, N., Morand, C., Milenkovic, D., Flavanol metabolites reduce monocyte adhesion to endothelial cells through modulation of expression of genes via p38-MAPK and p65-Nf-kB pathways. *Mol Nutr Food Res* 2014, *58*, 1016-1027, 10.1002/mnfr.201300658.
- [140] Milenkovic, D., Berghe, W. V., Morand, C., Claude, S., van de Sandt, A., Gorressen, S., Monfoulet, L. E., Chirumamilla, C. S., Declerck, K., Szic, K. S. V., Lahtela-Kakkonen, M., Gerhauser, C., Merx, M. W., Kelm, M., A systems biology network analysis of nutri(epi)genomic changes in endothelial cells exposed to epicatechin metabolites. *Sci Rep* 2018, *8*, 15487, 10.1038/s41598-018-33959-x.
- [141] Milenkovic, D., Declerck, K., Guttman, Y., Kerem, Z., Claude, S., Weseler, A. R., Bast, A., Schroeter, H., Morand, C., Vanden Berghe, W., (-)-Epicatechin metabolites promote vascular health



through epigenetic reprogramming of endothelial-immune cell signaling and reversing systemic low-grade inflammation. *Biochem Pharmacol* 2020, 173, 113699, 10.1016/j.bcp.2019.113699.

[142] Lacroix, S., Klicic Badoux, J., Scott-Boyer, M. P., Parolo, S., Matone, A., Priami, C., Morine, M. J., Kaput, J., Moco, S., A computationally driven analysis of the polyphenol-protein interactome. *Sci Rep* 2018, 8, 2232, 10.1038/s41598-018-20625-5.


[143] Krga, I., Tamaian, R., Mercier, S., Boby, C., Monfoulet, L. E., Glibetic, M., Morand, C., Milenkovic, D., Anthocyanins and their gut metabolites attenuate monocyte adhesion and transendothelial migration through nutrigenomic mechanisms regulating endothelial cell permeability. *Free Radic Biol Med* 2018, 124, 364-379, 10.1016/j.freeradbiomed.2018.06.027.

[144] Menezes, R., Rodriguez-Mateos, A., Kaltsatou, A., Gonzalez-Sarrias, A., Greyling, A., Giannaki, C., Andres-Lacueva, C., Milenkovic, D., Gibney, E. R., Dumont, J., Schar, M., Garcia-Aloy, M., Palma-Duran, S. A., Ruskovska, T., Maksimova, V., Combet, E., Pinto, P., Impact of Flavonols on Cardiometabolic Biomarkers: A Meta-Analysis of Randomized Controlled Human Trials to Explore the Role of Inter-Individual Variability. *Nutrients* 2017, 9, 10.3390/nu9020117.

[145] Milenkovic, D., Morand, C., Cassidy, A., Konic-Ristic, A., Tomas-Barberan, F., Ordovas, J. M., Kroon, P., De Caterina, R., Rodriguez-Mateos, A., Interindividual Variability in Biomarkers of Cardiometabolic Health after Consumption of Major Plant-Food Bioactive Compounds and the Determinants Involved. *Adv Nutr* 2017, 8, 558-570, 10.3945/an.116.013623.


## Figure and Table legends

**Figure 1:** Flow diagram of the study selection process.





**Figure 2:** Differentially expressed genes in mice, rats and rodents after oral treatment with flavanols – pure compounds or extracts from tea, cocoa, apple or grape seeds.


\*The number of differentially expressed genes in rodent target tissues was obtained by pooling together the differentially expressed genes in each specific tissue in mice and rats, and subsequent removal of duplicate genes. <sup>§</sup>All kinds of adipose tissues, including both brown and white adipose tissues of visceral, subcutaneous, and epididymal origin.




**Figure 3:** Functional enrichment analysis of the modulated genes in response to flavanol intake in liver (A, C), adipose tissues (B, D), muscles and aortas (E) of rodents (A-B-E: mouse; C-D-E: rat). Clustergrams were built on enriched pathways retrieved from KEGG using Enrichr. Enriched pathways were ranked based on their enrichment score and gene hierarchically clustered based on their association with the top enriched terms. Heatmap is proportional to p-value of the enriched terms. Gene modulation was *a posteriori* added onto the clustergram as well as gene coverage (expressed in percentage and ratio).










GSEA in Muscles	Mouse		Rat	
	Overlap	Adjusted P-value	Overlap	Adjusted P-value
Enriched Terms				
Adipocytokine signaling pathway			8,5	7,17E-10
AMPK signaling pathway			2,4	1,02E-03
Insulin resistance			7,3	5,72E-13
Fatty acid degradation	4,0	2,01E-02		
PPAR signaling pathway	3,5	1,60E-03	5,9	2,41E-07
Non-alcoholic fatty liver disease (NAFLD)	2,0	6,69E-03	3,3	2,64E-06
cAMP signaling pathway	1,4	1,44E-02		
Thermogenesis	1,7	1,21E-03		
Cardiac muscle contraction	2,6	4,18E-02		
C-type lectin receptor signaling pathway			2,7	7,51E-04
Fluid shear stress and atherosclerosis			2,1	1,33E-03
Hypertrophic cardiomyopathy (HCM)			3,5	4,81E-04
Hematopoietic cell lineage			3,2	5,62E-04
Osteoclast differentiation			2,3	1,03E-03
Huntington disease	2,1	1,16E-03		
Inflammatory bowel disease (IBD)			6,8	3,38E-06
Rheumatoid arthritis			3,6	4,76E-04
TNF signaling pathway			2,7	7,43E-04
Toll-like receptor signaling pathway			3,0	6,24E-04
Th17 cell differentiation			2,9	6,49E-04
IL-17 signaling pathway			3,3	5,38E-04
AGE-RAGE signaling pathway in diabetic complications			4,0	2,55E-05
FoxO signaling pathway			2,3	1,09E-03


GSEA in Aorta	Mouse		Rat	
	Overlap	Adjusted P-value	Overlap	Adjusted P-value
Enriched Terms				
Arginine biosynthesis	10,5	2,57E-03		
Hematopoietic cell lineage	3,2	2,09E-03		
HIF-1 signaling pathway	4,8	3,21E-06		
VEGF signaling pathway			3,4	3,30E-03
Fluid shear stress and atherosclerosis	7,0	2,31E-14	4,2	3,01E-09
Leukocyte transendothelial migration	4,3	4,72E-06	2,6	3,06E-04
Cell adhesion molecules (CAMs)	2,4	6,19E-04		
C-type lectin receptor signaling pathway			2,7	3,03E-04
Cytokine-cytokine receptor interaction			1,0	2,94E-03
MAPK signaling pathway			1,0	2,88E-03
MicroRNAs in cancer	1,8	2,48E-04		
Graft-versus-host disease			3,1	3,74E-03
NOD-like receptor signaling pathway	2,4	6,78E-05	1,5	1,17E-03
Insulin resistance	2,7	2,80E-03		
Non-alcoholic fatty liver disease (NAFLD)			2,0	6,11E-04
Type I diabetes mellitus			2,9	4,20E-03
Osteoclast differentiation			3,1	6,62E-06
Proteoglycans in cancer			1,5	1,19E-03
Relaxin signaling pathway			2,3	4,24E-04
Inflammatory bowel disease (IBD)			5,1	5,57E-05
Rheumatoid arthritis	4,8	6,06E-05	4,8	1,81E-06
IL-17 signaling pathway	5,5	1,87E-06	4,4	2,15E-06
TNF signaling pathway	7,3	1,47E-11	4,5	4,31E-08
NF-kappa B signaling pathway	3,9	1,10E-04	3,9	2,98E-06
AGE-RAGE signaling pathway in diabetic complications	9,9	1,27E-15	4,9	3,72E-08

**Figure 4:** Global Enrichment analysis in response to flavanols (A: mice; B: Rats). Functionally organized network connects the input genes modulated in response to flavanols and the top enriched KEGG pathways that predict the main functions modulated by flavanols.

A





B





**Figure 5:** Predicted regulators responsible to the observed gene modulation. Transcription factors (A) and miRNA (B) were predicted submitting gene dataset to HOMER and miRwalk respectively. For a tissue, scales are proportional to hits from each gene inputs.





**Figure 6:** Global network of interactions between genes identified as modulated by flavanols with potential transcriptional regulators (i.e. transcription factors) and post-transcriptional regulators (i.e. miRNAs). The total interactions between mRNAs (yellow nodes labelled with the protein coding gene name), transcription factors (red nodes) and miRNAs (blue nodes) in mouse (A) and in rat (B) were built using the cytoscape software.




**Table 1:** Genes mostly investigated in rodent studies using targeted approach for assessing gene expression. The symbol size (▪,•,◆) is proportional to the number of repeats in respective categories. Reported main effect of flavanols on the gene expression corresponds to the effect observed in >80% of the studies.

Gene	Main biological functions	Number of repeats	Tissues					Extracts				Pure compounds				Main effects of PP-rich supplementation on its expression		
			Liver	Adipose Tissues	Muscles	Vascular tissues	PBMCs	Tea Flavanols	Apple Flavanols	Grapeseed Flavanols	Cocoa Flavanols	Procyanidins	EGCG	Epicatechin	Catechin			
Abca1	Protein transporter	11	◆				◆			•		●		■				↑
Aca	Fatty Acid Synthesis	19	◆	◆						•		•		■	■	■	■	↓
Acox1	Fatty acid beta-oxidation	11	◆	◆	◆					●	•		•	■	■	■		↑
Cpt1a	Fatty acid beta-oxidation	14	◆	◆						●	•	•			■			↑
Fasn	Fatty Acid Synthesis	23	◆	◆						●	•	●		■	■			↓
Il6	Acute inflammation	19	◆	◆	◆	◆	◆			•	•	•	●	■	■	■	■	↓
Ppara	Metabolic regulation (Triglyceride level)	20	◆	◆	◆					•	•	•	●	■	■	■	■	↑
Pparγ	Metabolic regulation (glucose)	26	◆	◆						•		•	●	■	■	■	■	↓ ↑
Pparaγc1a	Metabolic regulation (glucose)	18	◆	◆								•	●	■	■	■		↑
Sirt1	Metabolic regulation	17	◆	◆	◆	◆				•	•	●		■	■	■	■	↑


Sre bf1	Lipid and cholesterol synthesis	20	◆ ◆	● ●	■ ■	↓
Tnf	Acute inflammation	28	◆ ◆ ◆ ◆	● ● ● ●	■ ■ ■ ■	↓
Ucp 1	Energy expenditure	15	◆	● ●	■ ■ ■ ■	↑

Nutrigenomic reveals the complex and multilevel action of dietary flavanols contributing to their strong potential to preserve cardiometabolic health.

Nutritional interventions  
with FLAVANOLS in  
cardiometabolic models



Collection of  
nutrigenomics data



- miRNAs
- Epigenetics
- Transcriptomics

Identification of the multilevel  
mechanism of action of flavanols  
responsive to their benefit effects  
on cardiometabolic health